Colorectal cancer (CRC), originating in the colon or rectum, remains one of the leading causes of cancer-related morbidity and mortality worldwide (1, 2). While the incidence is highest in developed nations, a rising trend has been observed across many low- and middle-income countries, underscoring its growing global health impact (3). Most CRC cases arise sporadically, often developing from dysplastic adenomatous polyps (4). During disease progression, metastasis to the liver and lungs occurs in 40–50% of patients, and approximately one-quarter of individuals present with liver metastases at diagnosis, indicating late-stage detection in many cases (5, 6). Established risk factors include inflammatory bowel disease, family history of CRC, elevated body mass index, smoking, sedentary lifestyles, and specific dietary patterns (7). Despite advances in screening and treatment, the prognosis remains poor for patients diagnosed at advanced stages (8). A comprehensive understanding of CRC epidemiology is therefore critical for informing prevention strategies, optimizing healthcare resource allocation, and improving outcomes.

Emerging economies are increasingly central to the global cancer burden due to rapid demographic and socioeconomic transitions, shifts in lifestyle, and evolving healthcare systems (9). Traditionally, the BRICS nations comprised Brazil, Russian Federation, India, China, and South Africa (10). However, as of January 1, 2024, the group has expanded to include Saudi Arabia, Egypt, the United Arab Emirates, Iran, and Ethiopia, forming a broader bloc often referred to as ‘BRICS-plus’ (11, 12). This ten-nation bloc represents a substantial portion of the global population and disease burden. Although these countries differ in geography and culture, they share common challenges, such as urbanization, aging populations, healthcare infrastructure disparities, and increasing exposure to modifiable CRC risk factors (13). However, systematic and comparative assessments of CRC incidence across this expanded BRICS group remain scarce, limiting efforts to identify disparities and guide policy development in these settings.

The Global Burden of Disease (GBD) 2021 study offers a robust and standardized framework for evaluating CRC burden across time and geography, incorporating data on incidence, mortality, and risk factors from a wide range of global sources (14). Leveraging such data, the age–period–cohort (APC) model enables a nuanced examination of temporal trends by disentangling the effects of biological aging, time-specific factors (e.g., screening practices or treatment advances), and generational shifts in risk exposure (15). Although previous analyses using GBD data have offered valuable insights, they have often lacked the resolution required for national-level decision-making and have rarely explored within-country heterogeneity—particularly among BRICS nations (16, 17). Addressing this gap is essential for designing context-specific interventions that can effectively target country-level trends.

In this study, we utilize the most recent GBD 2021 dataset to perform a comprehensive APC analysis of CRC incidence trends in BRICS countries from 1990 to 2021. By examining variations across age groups, calendar periods, and birth cohorts, we aim to characterize the evolving epidemiology of CRC at the national level. Our findings provide critical insights into demographic and temporal drivers of CRC incidence, which can support the development of targeted public health strategies, promote equitable cancer control, and contribute to reducing the burden of CRC in these rapidly transforming regions.

Table 1 presents the population, total number of incidence, all age incidence rate, ASIR, and net drift of CRC incidence. Globally, the number of incident CRC cases increased from 917,000 (95% UI: 866,000–952,000) in 1990 to 2,194,000 (95% UI: 2,001,000–2,359,000) in 2021, representing a 139.38% increase. The global ASIR also increased from 24.04 (95% UI: 22.54–25.01) in 1990 to 25.61 (95% UI: 23.32–27.52) per 100,000 population in 2021, reflecting a relative increase of 6.52%. Based on the APC model, the estimated global net drift in CRC incidence was 0.15% per year (95% CI: 0.12–0.19) from 1990 to 2021 ( Table 1 ).

From 1990 to 2021, considerable variation in ASIR was observed across BRICS countries. The largest increases were seen in Saudi Arabia, Egypt, and China. In Saudi Arabia, the ASIR rose from 7.05 (95% UI: 5.15–9.25) to 14.88 (95% UI: 12.12–18.16) per 100 000 population, an increase of 111.0%. Egypt experienced a similar rise, with ASIR increasing from 6.32 (95% UI: 5.59–7.20) in 1990 to 12.57 (95% UI: 10.41–15.33) per 100,000 population in 2021, a 98.9% increase. In China, the ASIR rose from 19.04 (95% UI: 16.46–21.81) to 31.44 (95% UI: 25.53–37.97) per 100,000 population, a 65.13% increase. In contrast, Ethiopia and the United Arab Emirates showed declining trends. In Ethiopia, the ASIR decreased from 21.32 (95% UI: 12.46–26.19) in 1990 to 16.41 (95% UI: 13.70–19.54) per 100,000 population in 2021, a 23.04% reduction. In the United Arab Emirates, the ASIR dropped from 21.16 (95% UI: 14.40–29.03) to 18.79 (95% UI: 14.27–26.88) per 100,000 population, a decrease of 11.2%. According to APC model estimates, the annual net drift in CRC incidence ranged from -1.16% (95% CI: -1.38, -0.93) in the Ethiopia to 2.78 (95% CI: 2.52, 3.04) in Egypt among BRICS countries ( Table 1 ).

This study applies the APC model to systematically analyze temporal trends in CRC incidence at both global and BRICS country levels. Compared with prior analyses based on GBD data (16, 17, 29), our primary contribution lies in disentangling the distinct contributions of age, period, and cohort effects to observed incidence trends. Additionally, we estimated local drift values across age groups and tracked age-specific incidence redistributions, offering a more nuanced understanding of shifting CRC dynamics from 1990 to 2021. These analytical innovations provide actionable insights for policymakers and public health professionals, particularly in designing prevention strategies tailored to specific age groups and birth cohorts.

Between 1990 and 2021, global CRC incidence rose by 139.38%, accompanied by a 6.52% increase in the ASIR. This upward trend is primarily attributed to population aging, lifestyle-related risk factors (including poor diet, sedentary behavior, and obesity), and improved early detection (30, 31). Despite advances in diagnosis and treatment, significant disparities persist in prevention, early detection, and timely access to treatment, particularly in low- and middle-income countries, thereby contributing to the continued rise in global CRC incidence. The global net drift of 0.15% per year, along with predominantly positive local drift values across age groups, suggests that the increase in incidence reflects a true elevation in generational risk, rather than demographic changes alone. The relative stability of period effects at the global level indicates limited progress in population-wide screening and diagnostic interventions over the past three decades. Cohort effects, particularly among individuals born after 1970, showed an overall increase before leveling off in more recent birth cohorts. This pattern is plausibly linked to greater exposure to modifiable lifestyle factors—such as Westernized dietary patterns, reduced physical activity, and rising obesity (32). The subsequent plateau may reflect a stabilization of these exposures alongside earlier detection as public awareness improved and screening programs expanded (33, 34). Globally, males consistently exhibit higher CRC incidence than females, likely reflecting sex-specific differences in behavior, metabolism, and biology—on average, men have greater lifetime exposure to tobacco and alcohol, more central adiposity with adverse metabolic profiles, lower screening participation, and potentially weaker hormonal protection (35, 36).

Our analysis reveals substantial regional heterogeneity in CRC incidence. Among BRICS countries, Saudi Arabia, Egypt, and China experienced the most pronounced increases in ASIR, with Saudi Arabia reporting a striking 111.02% rise. These increases are largely driven by rapid urbanization, shifts in lifestyle (e.g., increased consumption of high-fat, low-fiber diets), and aging populations (37). In Saudi Arabia, CRC has become the most common malignancy among men and the third most common among women, with over 66% of cases diagnosed at advanced stages (38). Contributing factors include widespread physical inactivity, high obesity prevalence, and limited public awareness of screening programs (39). Egypt and China also experienced marked ASIR increases, underscoring the role of lifestyle changes and demographic transitions in escalating CRC burden. In contrast, Ethiopia demonstrated a 23.04% decline in ASIR and a negative net drift–possibly reflecting a youthful population structure, incomplete cancer registration, and low screening coverage (40). The United Arab Emirates similarly exhibited a modest decline in ASIR, potentially due to demographic shifts, including a large influx of younger migrant workers, as well as underreporting and diagnostic delays linked to underdeveloped cancer surveillance systems (41). However, these observed declines may not necessarily reflect a true reduction in disease burden but rather underscore the need for enhanced cancer registry systems and improved surveillance accuracy.

APC trajectories in Brazil, China, Egypt, Iran, and Saudi Arabia consistently revealed rising ASIR, positive net drift, and pronounced cohort effects, particularly among individuals born after 1970. These patterns reflect the convergence of epidemiological transitions with regional risk exposures such as dietary Westernization, increased obesity prevalence, and insufficient early screening (42). In China and Egypt, the CRC burden has increasingly shifted toward older adults due to both population aging and expanded healthcare access. These findings underscore the need to strengthen organized screening for adults ≥ 60 years—especially men, who have lower uptake–and to expand colonoscopy/fecal immunochemical test (FIT) coverage through insured primary care (43). In contrast, Saudi Arabia and the United Arab Emirates showed a trend toward earlier-onset CRC, with increasing incidence among individuals aged 15–49 years. This concerning shift highlights the need to revisit current screening guidelines, which often exclude younger age groups despite rising risk. In these settings, earlier screening may be justified where local risk, capacity, and cost-effectiveness permit (44, 45). Brazil also faces a growing CRC burden, particularly among younger adults, likely due to urbanization-related lifestyle changes and delayed implementation of national screening programs (46). During program expansion, opportunistic coverage of younger mid-adult ages may serve as a pragmatic interim approach, together with interventions to reduce obesity and sedentary time in young men (47, 48). Across these countries, the APC model consistently demonstrates steep age effects and amplified cohort effects—suggesting that recent generations face higher risks driven by cumulative exposure to carcinogenic behaviors and environments (49). These findings emphasize the need for generation-specific interventions and the integration of CRC prevention into broader non-communicable disease strategies.

India and Ethiopia exhibited declining cohort effects and negative net drift. In India, early public health interventions—such as the National Cancer Control Program, which emphasizes education and primary prevention—may have contributed to this trend. Notably, pilot projects implemented under the program that integrated community education, primary-care FIT, and clear referral/navigation pathways have reported higher screening completion (50). However, the absence of a nationwide, population-based CRC screening program limits interpretability, as undetected or unreported cases may obscure the true disease burden (51). Ethiopia’s declining CRC incidence likely reflects a combination of demographic and healthcare system factors. The nation’ s predominantly young population lowers overall CRC risk, while limited healthcare infrastructure contributes to underreporting and underdiagnosis. Restricted access to medical services, substantial urban-rural disparities, and limited diagnostic capacity further reinforce this pattern. Moreover, the absence of population-based CRC screening and incomplete cancer registration may obscure the true disease burden, a challenge commonly observed in low-resource settings (52, 53). Beyond these health-system considerations, the observed declines in both countries may also be consistent with cohort-level shifts in exposures—toward healthier dietary patterns, more favorable physical-activity/adiposity trajectories, reduced tobacco/alcohol uptake, and improved early-life environments (54).

South Africa and the Russian Federation displayed more complex APC patterns. In South Africa, the observed increase in cohort effects and positive drift among older adults may reflect rising life expectancy and improved registry coverage through the South African National Cancer Registry (55). The Russian Federation showed a fluctuating cohort pattern—initially increasing then decreasing—possibly influenced by historical clinical screening policies and recent changes in healthcare access. Nonetheless, the persistent elevation in CRC risk among younger males in Russia suggests emerging exposures such as alcohol, tobacco, and processed food consumption warrant further investigation (56). The United Arab Emirates demonstrated a unique APC trajectory. While the age effect followed expected patterns, cohort effects indicated a shift in risk toward individuals born after 1980. This trend may be linked to demographic changes and increasing adoption of Westernized lifestyles in a highly mobile population (57). The relatively flat period effects suggest that recent healthcare reforms have yet to meaningfully impact CRC incidence trends.

Several limitations should be acknowledged. First, national-level data may obscure subnational disparities, particularly in countries with heterogeneous access to healthcare and varying socioeconomic conditions. In addition, data quality varies across BRICS—for example, incomplete cancer registries in Ethiopia may underestimate true incidence, while migration patterns such as the influx of young migrant workers in the UAE could distort age-specific trends and cohort analyses (41). Second, although GBD estimates are standardized, variability in data quality and diagnostic practices across countries may introduce bias. Third, the use of five-year intervals in the APC model may limit detection of subtle temporal trends, especially for early-onset CRC. Moreover, APC analyses are ecological and not designed for causal inference. They cannot separate the effects of diet, screening uptake, and healthcare expansion. Follow-up studies using individual-level or longitudinal data are needed to clarify these relationships. Finally, recent public health shifts and interventions may not yet be fully reflected in our study period. Future studies should incorporate longitudinal cohort datasets, subnational analyses, and country-specific APC models to further elucidate evolving CRC risk patterns in the BRICS nations and beyond.

In general, this study provides a comprehensive analysis of CRC incidence trends from 1990 to 2021 using an age–period–cohort framework across global and BRICS contexts. By delineating the independent contributions of age, period, and cohort effects, we reveal that the increasing CRC burden is not solely attributable to demographic shifts but reflects rising generational risk, particularly among individuals born after 1970. These findings highlight significant epidemiological transitions in rapidly developing economies, including a shift toward earlier-onset CRC in some settings. The persistence of positive local and net drifts, especially in countries such as China, Saudi Arabia, and Egypt, underscores the urgent need for context-specific, generation-targeted prevention strategies, as well as a re-examination of existing screening guidelines to encompass younger populations. Our results also underscore the importance of strengthening cancer surveillance systems and expanding equitable access to early detection and treatment. Future efforts should prioritize longitudinal, subnational, and policy-integrated analyses to further inform tailored interventions aimed at reversing the global rise in CRC incidence.